13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Frankfurt |
94,080 |
12.07.24 12:36:48 |
+0,250 |
+0,27% |
0,000 |
0,000 |
94,170 |
94,080 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
1.002,500 |
12.07.24 15:30:58 |
+20,100 |
+2,05% |
0,000 |
0,000 |
989,400 |
1.002,500 |